Yamamoto Miho, Ozawa Soji, Koyanagi Kazuo, Ninomiya Yamato, Hara Hitoshi, Kazuno Akihito, Yatabe Kentaro, Higuchi Tadashi, Nakamura Kenji, Nabeshima Kazuhito, Sato Yasufumi
Department of Gastroenterological Surgery, Tokai University School of Medicine.
New Industry Creation Hatchery Center, Tohoku University.
Tohoku J Exp Med. 2022 Apr 20;256(4):291-301. doi: 10.1620/tjem.2022.J005. Epub 2022 Mar 17.
Vasohibin-1 (VASH1) is an angiogenesis inhibitor, while vasohibin-2 (VASH2) is a proangiogenic factor. The roles of VASH1 and VASH2 expression in gastroenterological cancers remain unclear. We searched for relevant literature, specifically studies on gastroenterological cancer, and evaluated the relationship between VASH expression and clinical outcomes. Nine studies on VASH1 involving 1,574 patients were included. VASH1 expression was associated with the TNM stage [OR (odds ratio) 2.05, 95% CI (confidence interval) 1.24-3.40], lymph node metastasis (OR 1.79, 95% CI 1.24-2.58), lymphatic invasion (OR 1.95, 95% CI 1.41-2.68), and venous invasion (OR 2.49, 95% CI 1.60-3.88); poor clinical outcomes were associated with high VASH1 expression. High VASH1 expression was associated with a significantly shorter overall survival (OS) [HR (hazard ratio) 1.69, 95% CI 1.25-2.29] and disease-free survival (DFS) (HR 2.01, 95% CI 1.28-3.15). Three studies on VASH2 involving 469 patients were analyzed. VASH2 expression was associated with the TNM stage (OR 4.21, 95% CI 1.89-9.51) and venous invasion (OR 2.10, 95% CI 1.15-3.84); poor clinical outcomes were associated with high VASH2 expression. High VASH2 expression was associated with a significantly lower OS (HR 1.61, 95% CI 1.09-2.37). In conclusion, high VASH1 and VASH2 expression levels were associated with poor clinical outcomes and prognosis in patients with gastroenterological cancers.
血管抑制素-1（VASH1）是一种血管生成抑制剂，而血管抑制素-2（VASH2）是一种促血管生成因子。VASH1和VASH2表达在胃肠癌中的作用仍不清楚。我们检索了相关文献，特别是关于胃肠癌的研究，并评估了VASH表达与临床结局之间的关系。纳入了9项关于VASH1的研究，涉及1574例患者。VASH1表达与TNM分期[比值比（OR）2.05，95%置信区间（CI）1.24 - 3.40]、淋巴结转移（OR 1.79，95% CI 1.24 - 2.58）、淋巴管侵犯（OR 1.95，95% CI 1.41 - 2.68）和静脉侵犯（OR 2.49，95% CI 1.60 - 3.88）相关；临床结局较差与VASH1高表达相关。VASH1高表达与总生存期（OS）显著缩短[风险比（HR）1.69，95% CI 1.25 - 2.29]和无病生存期（DFS）（HR 2.01，95% CI 1.28 - 3.15）相关。分析了3项关于VASH2的研究，涉及469例患者。VASH2表达与TNM分期（OR 4.21，95% CI 1.89 - 9.51）和静脉侵犯（OR 2.10，95% CI 1.15 - 3.84）相关；临床结局较差与VASH2高表达相关。VASH2高表达与OS显著降低（HR 1.61，95% CI 1.09 - 2.37）相关。总之，VASH1和VASH2高表达水平与胃肠癌患者的临床结局较差及预后不良相关。
